{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T23:58:35Z","timestamp":1776297515398,"version":"3.50.1"},"reference-count":46,"publisher":"Walter de Gruyter GmbH","issue":"4","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100015027","name":"Vice Chancellor for Research and Technology, Hamadan University of Medical Sciences","doi-asserted-by":"publisher","award":["Grant No. 140204273216"],"award-info":[{"award-number":["Grant No. 140204273216"]}],"id":[{"id":"10.13039\/501100015027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_hmbci-2024-0074_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      Non-alcoholic fatty liver disease (NAFLD), recently reclassified as metabolic dysfunction-associated fatty liver disease (MAFLD), can also manifest in patients classified as non-MAFLD who do not meet MAFLD criteria. The involvement of cortisol and thyroid hormones may play a role in the pathogenesis of FLD by modifying the metabolism of specific lipoproteins, particularly\n                      <jats:italic>apolipoprotein M<\/jats:italic>\n                      (\n                      <jats:italic>Apo M<\/jats:italic>\n                      ). This study investigated cortisol and thyroid hormones levels and\n                      <jats:italic>Apo M<\/jats:italic>\n                      gene expression in white blood cells (WBCs) of individuals with MAFLD, non-MAFLD, and healthy controls.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2024-0074_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The serum and WBCs of the study subjects were collected from patients with FLD (n=99) including 58 MAFLD and 41 non-MAFLD and healthy individuals (n=23). To investigate the gene expression of\n                      <jats:italic>Apo M<\/jats:italic>\n                      and thyroid and cortisol hormones, qRT-PCR and ELISA methods were used, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2024-0074_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The\n                      <jats:italic>Apo M<\/jats:italic>\n                      gene expression was significantly lower in FLD patients, both non-MAFLD, and MAFLD patients compared to the control group (p&lt;0.05). Total T4 and TSH hormone levels in the MAFLD patients were significantly decreased and increased compared to the control group, respectively (p&lt;0.05). The cortisol level was significantly elevated in the FLD and MAFLD patients compared to the control group (p&lt;0.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2024-0074_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Alterations in\n                      <jats:italic>Apo M<\/jats:italic>\n                      gene expression also cortisol and thyroid hormones levels in non-MAFLD patients were milder than MAFLD patients when compared to the control. Also, likely\n                      <jats:italic>Apo M<\/jats:italic>\n                      may be involved in FLD pathogenesis.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/hmbci-2024-0074","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T02:56:42Z","timestamp":1739847402000},"page":"157-165","source":"Crossref","is-referenced-by-count":1,"title":["Differential levels of thyroid hormones, cortisol, and apolipoprotein M in fatty liver disease"],"prefix":"10.1515","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2589-2191","authenticated-orcid":false,"given":"Amir Mohammad","family":"Zargar","sequence":"first","affiliation":[{"name":"Department of Clinical Biochemistry, Faculty of Medicine , Hamadan University of Medical Sciences , Hamadan , Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7243-660X","authenticated-orcid":false,"given":"Heidar","family":"Tayebinia","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Faculty of Medicine , Hamadan University of Medical Sciences , Hamadan , Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Hasanzarrini","sequence":"additional","affiliation":[{"name":"Clinical Research Development Unit of Shahid Beheshti Hospital , Hamadan University of Medical Sciences , Hamadan , Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad","family":"Bahiraei","sequence":"additional","affiliation":[{"name":"Department of Radiology, School of Medicine , Hamadan University of Medical Sciences , Hamadan , Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0388-8095","authenticated-orcid":false,"given":"Sina","family":"Mohagheghi","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Faculty of Medicine , Hamadan University of Medical Sciences , Hamadan , Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"2025121908111615780_j_hmbci-2024-0074_ref_001","doi-asserted-by":"crossref","unstructured":"Khajehahmadi, Z, Nikeghbalian, S, Roshanaei, G, Mohagheghi, S. Increasing prevalence and high survival rate of liver transplanted patients with NASH and PSC cirrhosis. Arch Iran Med 2024;27:23\u20139. https:\/\/doi.org\/10.34172\/aim.2024.04.","DOI":"10.34172\/aim.2024.04"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_002","doi-asserted-by":"crossref","unstructured":"Sun, L, Yue, Z, Wang, L. Research on the function of epigenetic regulation in the inflammation of non-alcoholic fatty liver disease. Life Med 2024;3:lnae030. https:\/\/doi.org\/10.1093\/lifemedi\/lnae030.","DOI":"10.1093\/lifemedi\/lnae030"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_003","doi-asserted-by":"crossref","unstructured":"Bae, SDW, George, J, Qiao, L. From MAFLD to hepatocellular carcinoma and everything in between. Chin Med J (Engl) 2022;135:547\u201356. https:\/\/doi.org\/10.1097\/cm9.0000000000002089.","DOI":"10.1097\/CM9.0000000000002089"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_004","doi-asserted-by":"crossref","unstructured":"Fan, H, Liu, Z, Zhang, P, Wu, S, Han, X, Huang, Y, et al.. Characteristics and long-term mortality of patients with non-MAFLD hepatic steatosis. Hepatol Int 2023;17:615\u201325. https:\/\/doi.org\/10.1007\/s12072-023-10512-1.","DOI":"10.1007\/s12072-023-10512-1"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_005","doi-asserted-by":"crossref","unstructured":"Ye, Q, Zou, B, Yeo, YH, Li, J, Huang, DQ, Wu, Y, et al.. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020;5:739\u201352. https:\/\/doi.org\/10.1016\/s2468-1253(20)30077-7.","DOI":"10.1016\/S2468-1253(20)30077-7"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_006","doi-asserted-by":"crossref","unstructured":"Denkmayr, L, Feldman, A, Stechemesser, L, Eder, SK, Zandanell, S, Schranz, M, et al.. Lean patients with non-alcoholic fatty liver disease have a severe histological phenotype similar to obese patients. J Clin Med 2018;7. https:\/\/doi.org\/10.3390\/jcm7120562.","DOI":"10.3390\/jcm7120562"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_007","doi-asserted-by":"crossref","unstructured":"Gariani, K, Jornayvaz, FR. Pathophysiology of NASH in endocrine diseases. Endocr Connect 2021;10:R52\u2013r65. https:\/\/doi.org\/10.1530\/ec-20-0490.","DOI":"10.1530\/EC-20-0490"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_008","unstructured":"Lam, KS, Chan, MK, Yeung, RT. High-density lipoprotein cholesterol, hepatic lipase and lipoprotein lipase activities in thyroid dysfunction--effects of treatment. Q J Med 1986;59:513\u201321."},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_009","doi-asserted-by":"crossref","unstructured":"Tan, KC, Shiu, SW, Kung, AW. Plasma cholesteryl ester transfer protein activity in hyper- and hypothyroidism. J Clin Endocrinol Metab 1998;83:140\u20133. https:\/\/doi.org\/10.1210\/jcem.83.1.4491.","DOI":"10.1210\/jc.83.1.140"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_010","doi-asserted-by":"crossref","unstructured":"Duntas, LH. Thyroid disease and lipids. Thyroid 2002;12:287\u201393. https:\/\/doi.org\/10.1089\/10507250252949405.","DOI":"10.1089\/10507250252949405"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_011","doi-asserted-by":"crossref","unstructured":"Adcock, IM, Mumby, S. Glucocorticoids. Handb Exp Pharmacol 2017;237:171\u201396. https:\/\/doi.org\/10.1007\/164_2016_98.","DOI":"10.1007\/164_2016_98"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_012","doi-asserted-by":"crossref","unstructured":"Vandewalle, J, Luypaert, A, De Bosscher, K, Libert, C. Therapeutic mechanisms of glucocorticoids. Trends Endocrinol Metab 2018;29:42\u201354. https:\/\/doi.org\/10.1016\/j.tem.2017.10.010.","DOI":"10.1016\/j.tem.2017.10.010"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_013","doi-asserted-by":"crossref","unstructured":"Yang, M, Ma, F, Guan, M. Role of steroid hormones in the pathogenesis of nonalcoholic fatty liver disease. Metabolites 2021;11. https:\/\/doi.org\/10.3390\/metabo11050320.","DOI":"10.3390\/metabo11050320"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_014","doi-asserted-by":"crossref","unstructured":"Torre, P, Motta, BM, Sciorio, R, Masarone, M, Persico, M. Inflammation and fibrogenesis in MAFLD: role of the hepatic immune system. Front Med (Lausanne) 2021;8:781567. https:\/\/doi.org\/10.3389\/fmed.2021.781567.","DOI":"10.3389\/fmed.2021.781567"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_015","doi-asserted-by":"crossref","unstructured":"Chen, S, Guo, H, Xie, M, Zhou, C, Zheng, M. Neutrophil: an emerging player in the occurrence and progression of metabolic associated fatty liver disease. Int Immunopharmacol 2021;97:107609. https:\/\/doi.org\/10.1016\/j.intimp.2021.107609.","DOI":"10.1016\/j.intimp.2021.107609"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_016","doi-asserted-by":"crossref","unstructured":"Xu, N, Dahlb\u00e4ck, B. A novel human apolipoprotein (apoM). J Biol Chem 1999;274:31286\u201390. https:\/\/doi.org\/10.1074\/jbc.274.44.31286.","DOI":"10.1074\/jbc.274.44.31286"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_017","doi-asserted-by":"crossref","unstructured":"Mulya, A, Seo, J, Brown, AL, Gebre, AK, Boudyguina, E, Shelness, GS, et al.. Apolipoprotein M expression increases the size of nascent pre beta HDL formed by ATP binding cassette transporter A1. J Lipid Res 2010;51:514\u201324. https:\/\/doi.org\/10.1194\/jlr.m002162.","DOI":"10.1194\/jlr.M002162"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_018","doi-asserted-by":"crossref","unstructured":"Wolfrum, C, Poy, MN, Stoffel, M. Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat Med 2005;11:418\u201322. https:\/\/doi.org\/10.1038\/nm1211.","DOI":"10.1038\/nm1211"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_019","doi-asserted-by":"crossref","unstructured":"Cheng, G, Zheng, L. Regulation of the apolipoprotein M signaling pathway: a review. J Recept Signal Transduct Res 2022;42:285\u201392. https:\/\/doi.org\/10.1080\/10799893.2021.1924203.","DOI":"10.1080\/10799893.2021.1924203"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_020","doi-asserted-by":"crossref","unstructured":"Eslam, M, Newsome, PN, Sarin, SK, Anstee, QM, Targher, G, Romero-Gomez, M, et al.. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 2020;73:202\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.039.","DOI":"10.1016\/j.jhep.2020.07.045"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_021","doi-asserted-by":"crossref","unstructured":"Schmittgen, TD, Livak, KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008;3:1101\u20138. https:\/\/doi.org\/10.1038\/nprot.2008.73.","DOI":"10.1038\/nprot.2008.73"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_022","doi-asserted-by":"crossref","unstructured":"Matthews, DR, Hosker, JP, Rudenski, AS, Naylor, BA, Treacher, DF, Turner, RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412\u20139. https:\/\/doi.org\/10.1007\/bf00280883.","DOI":"10.1007\/BF00280883"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_023","doi-asserted-by":"crossref","unstructured":"Wang, S, Zhang, Q, Qin, B. Association between remnant cholesterol and insulin resistance levels in patients with metabolic-associated fatty liver disease. Sci Rep 2024;14:4596. https:\/\/doi.org\/10.1038\/s41598-024-55282-4.","DOI":"10.1038\/s41598-024-55282-4"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_024","doi-asserted-by":"crossref","unstructured":"Lin, S, Huang, J, Wang, M, Kumar, R, Liu, Y, Liu, S, et al.. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int 2020;40:2082\u20139. https:\/\/doi.org\/10.1111\/liv.14548.","DOI":"10.1111\/liv.14548"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_025","doi-asserted-by":"crossref","unstructured":"Sohn, W, Kwon, HJ, Chang, Y, Ryu, S, Cho, YK. Liver fibrosis in Asians with metabolic dysfunction-associated fatty liver disease. Clin Gastroenterol Hepatol 2022;20:e1135\u201348. https:\/\/doi.org\/10.1016\/j.cgh.2021.06.042.","DOI":"10.1016\/j.cgh.2021.06.042"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_026","doi-asserted-by":"crossref","unstructured":"Loomba, R, Friedman, SL, Shulman, GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 2021;184:2537\u201364. https:\/\/doi.org\/10.1016\/j.cell.2021.04.015.","DOI":"10.1016\/j.cell.2021.04.015"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_027","doi-asserted-by":"crossref","unstructured":"Couillard, C, Bergeron, N, Prud\u2019homme, D, Bergeron, J, Tremblay, A, Bouchard, C, et al.. Gender difference in postprandial lipemia: importance of visceral adipose tissue accumulation. Arterioscler Thromb Vasc Biol 1999;19:2448\u201355. https:\/\/doi.org\/10.1161\/01.atv.19.10.2448.","DOI":"10.1161\/01.ATV.19.10.2448"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_028","doi-asserted-by":"crossref","unstructured":"Nielsen, S, Guo, Z, Johnson, CM, Hensrud, DD, Jensen, MD. Splanchnic lipolysis in human obesity. J Clin Invest 2004;113:1582\u20138. https:\/\/doi.org\/10.1172\/jci200421047.","DOI":"10.1172\/JCI200421047"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_029","doi-asserted-by":"crossref","unstructured":"Jiang, H, Yan, WH, Li, CJ, Wang, AP, Dou, JT, Mu, YM. Elevated white blood cell count is associated with higher risk of glucose metabolism disorders in middle-aged and elderly Chinese people. Int J Environ Res Public Health 2014;11:5497\u2013509. https:\/\/doi.org\/10.3390\/ijerph110505497.","DOI":"10.3390\/ijerph110505497"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_030","doi-asserted-by":"crossref","unstructured":"Zhang, X, Zhang, P, Gao, J, Huang, Q. Autophagy dysregulation caused by ApoM deficiency plays an important role in liver lipid metabolic disorder. Biochem Biophys Res Commun 2018;495:2643\u20138. https:\/\/doi.org\/10.1016\/j.bbrc.2017.12.148.","DOI":"10.1016\/j.bbrc.2017.12.148"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_031","doi-asserted-by":"crossref","unstructured":"Shi, Y, Lam, SM, Liu, H, Luo, G, Zhang, J, Yao, S, et al.. Comprehensive lipidomics in apoM(-\/-) mice reveals an overall state of metabolic distress and attenuated hepatic lipid secretion into the circulation. J Genet Genomics 2020;47:523\u201334. https:\/\/doi.org\/10.1016\/j.jgg.2020.08.003.","DOI":"10.1016\/j.jgg.2020.08.003"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_032","doi-asserted-by":"crossref","unstructured":"Bril, F, Pearce, RW, Collier, TS, McPhaul, MJ. Differences in HDL-bound apolipoproteins in patients with advanced liver fibrosis due to nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2022;108:42\u201351. https:\/\/doi.org\/10.1210\/clinem\/dgac565.","DOI":"10.1210\/clinem\/dgac565"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_033","doi-asserted-by":"crossref","unstructured":"Jiang, J, Wu, C, Luo, G, Zheng, L, Chen, L, Zhang, X, et al.. Expression of apolipoprotein M in human hepatocellular carcinoma tissues. Acta Histochem 2011;113:53\u20137. https:\/\/doi.org\/10.1016\/j.acthis.2009.08.005.","DOI":"10.1016\/j.acthis.2009.08.005"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_034","unstructured":"Feingold, KR, Grunfeld, C. The effect of inflammation and infection on lipids and lipoproteins. In: Feingold, KR, Anawalt, B, Blackman, MR, Boyce, A, Chrousos, G, Corpas, E, editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2022."},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_035","doi-asserted-by":"crossref","unstructured":"Khovidhunkit, W, Kim, MS, Memon, RA, Shigenaga, JK, Moser, AH, Feingold, KR, et al.. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004;45:1169\u201396. https:\/\/doi.org\/10.1194\/jlr.r300019-jlr200.","DOI":"10.1194\/jlr.R300019-JLR200"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_036","doi-asserted-by":"crossref","unstructured":"Feingold, KR, Shigenaga, JK, Chui, LG, Moser, A, Khovidhunkit, W, Grunfeld, C. Infection and inflammation decrease apolipoprotein M expression. Atherosclerosis 2008;199:19\u201326. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2007.10.007.","DOI":"10.1016\/j.atherosclerosis.2007.10.007"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_037","unstructured":"Du, W, Wang, L, Li, H, Liu, Y, Shen, T, Hu, M. Association of serum level of apolipoprotein M with disease activity in systemic lupus erythematosus. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2015;40:367\u201372. https:\/\/doi.org\/10.11817\/j.issn.1672-7347.2015.04.005."},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_038","doi-asserted-by":"crossref","unstructured":"Chen, K, Chen, L, Dai, J, Ye, H. MAFLD in patients with Cushing\u2019s disease is negatively associated with low free thyroxine levels rather than with cortisol or TSH levels. Int J Endocrinol 2023;2023:6637396. https:\/\/doi.org\/10.1155\/2023\/6637396.","DOI":"10.1155\/2023\/6637396"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_039","doi-asserted-by":"crossref","unstructured":"Chen, S, Jin, Y, Xu, M, Zhang, P, Zhou, Y, Qian, X, et al.. Relationship between thyroid hormone and liver steatosis analysis parameter in obese participants: a case-control study. Diabetes Metab Syndr Obes 2022;15:887\u201396. https:\/\/doi.org\/10.2147\/dmso.s356882.","DOI":"10.2147\/DMSO.S356882"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_040","doi-asserted-by":"crossref","unstructured":"Shibli-Rahhal, A, Van Beek, M, Schlechte, JA. Cushing\u2019s syndrome. Clin Dermatol 2006;24:260\u20135. https:\/\/doi.org\/10.1016\/j.clindermatol.2006.04.012.","DOI":"10.1016\/j.clindermatol.2006.04.012"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_041","doi-asserted-by":"crossref","unstructured":"Chanson, P, Salenave, S. Metabolic syndrome in Cushing\u2019s syndrome. Neuroendocrinology 2010;92:96\u2013101. https:\/\/doi.org\/10.1159\/000314272.","DOI":"10.1159\/000314272"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_042","doi-asserted-by":"crossref","unstructured":"Nicolaides, NC, Kyratzi, E, Lamprokostopoulou, A, Chrousos, GP, Charmandari, E. Stress, the stress system and the role of glucocorticoids. Neuroimmunomodulation 2015;22:6\u201319. https:\/\/doi.org\/10.1159\/000362736.","DOI":"10.1159\/000362736"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_043","doi-asserted-by":"crossref","unstructured":"Benker, G, Raida, M, Olbricht, T, Wagner, R, Reinhardt, W, Reinwein, D. TSH secretion in Cushing\u2019s syndrome: relation to glucocorticoid excess, diabetes, goitre, and the \u2019sick euthyroid syndrome. Clin Endocrinol (Oxf) 1990;33:777\u201386. https:\/\/doi.org\/10.1111\/j.1365-2265.1990.tb03915.x.","DOI":"10.1111\/j.1365-2265.1990.tb03915.x"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_044","doi-asserted-by":"crossref","unstructured":"Parker, JC, Moraitis, AG, Belanoff, JK. Biochemical and radiological changes in liver steatosis following mifepristone treatment in patients with hypercortisolism. AACE Clin Case Rep 2022;8:25\u20139. https:\/\/doi.org\/10.1016\/j.aace.2021.07.001.","DOI":"10.1016\/j.aace.2021.07.001"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_045","doi-asserted-by":"crossref","unstructured":"Hubel, JM, Schmidt, SA, Mason, RA, Haenle, MM, Oeztuerk, S, Koenig, W, et al.. Influence of plasma cortisol and other laboratory parameters on nonalcoholic fatty liver disease. Horm Metab Res 2015;47:479\u201384. https:\/\/doi.org\/10.1055\/s-0034-1389982.","DOI":"10.1055\/s-0034-1389982"},{"key":"2025121908111615780_j_hmbci-2024-0074_ref_046","doi-asserted-by":"crossref","unstructured":"Meyer, G, Gruendl, M, Chifu, I, Hahner, S, Werner, J, Wei\u00df, J, et al.. Glucocorticoid replacement for adrenal insufficiency and the development of non-alcoholic fatty liver disease. J Clin Med 2023;12. https:\/\/doi.org\/10.3390\/jcm12196392.","DOI":"10.3390\/jcm12196392"}],"container-title":["Hormone Molecular Biology and Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2024-0074\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2024-0074\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T08:11:31Z","timestamp":1766131891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2024-0074\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":46,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2,19]]},"published-print":{"date-parts":[[2025,12,19]]}},"alternative-id":["10.1515\/hmbci-2024-0074"],"URL":"https:\/\/doi.org\/10.1515\/hmbci-2024-0074","relation":{},"ISSN":["1868-1891"],"issn-type":[{"value":"1868-1891","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]}}}